Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum

Haematologica

Volumn 96, Issue 4, 2011, Pages 491-493

  Breem, Dimitri A ^a   Löwenberg, Bob ^b  

^a Hospital Network Antwerp   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL PRACTICE; EDITORIAL; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; MEDICAL DECISION MAKING; MONOSOMY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROGNOSIS; TREATMENT PLANNING;

HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MONOSOMY; PROGNOSIS;

EID: 79953878823     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.043208     Document Type: Editorial

References (14)

1. Lowenberg B, Downing JR, and Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-62.
2. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner AK, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
3. Burnett A, Wetzler M, and Lowenberg B. Therapeutic Advances in Acute Myeloid Leukemia. J Clin Oncol. 2011;29(5):487-94.
4. Xie B, Othus M, Medeiros BC, Fang M, Appelbaum FR, Estey EH. Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. Haematologica 2011;96(4): 631-2.
5. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KBJ, Mellink CHM, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-7.
6. Löwenberg B, Ossenkoppele GJ, Van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-48.
7. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-65.
8. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116(13):2224-8.
9. Lowenberg B, Pabst T, Vellenga E, Van Putten W, Schouten HC, Graux C, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027-36.
10. Patnaik MM, Hanson CA, Hodnefield JM, Knudson R, Van Dyke DL, Tefferi A. Monosomal karyotype in myelodysplastic syndromes with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia. 2011;25(2):266-70.
11. Estey EH, Pierce S, Keating MJ. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica. 2000;85(3):246-9.
12. Oran B, Dolan M, Cao Q, Brunstein C, Warlick E, Weisdorf D. Monosomal karyotype provides better prognostic prediction after allo-geneic stem cell transplantation in patients with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2011;17(3):356-64.
13. Cornelissen JJ, Van Putten WLJ, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658-66.
14. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349-61.